论文部分内容阅读
贝伐单抗(bevacizumab)是抗血管内皮生长因子(VEGF)的单克隆抗体。研究证实,贝伐单抗联合治疗,能增加铂类为基础的双药化疗方案治疗进展期NSCLC的疗效。本文就贝伐单抗联合化疗治疗非小细胞肺癌的的研究进展作一综述。
Bevacizumab is a monoclonal antibody against vascular endothelial growth factor (VEGF). Study confirmed that bevacizumab combination therapy can increase the platinum-based dual-drug chemotherapy in the treatment of advanced NSCLC. This article reviews the progress of bevacizumab combined with chemotherapy in the treatment of non-small cell lung cancer.